Sart-Tilman, Belgium

Isabelle Renard


 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Isabelle Renard

Introduction

Isabelle Renard is a notable inventor based in Sart-Tilman, Belgium. She has made significant contributions to the field of molecular biology, particularly in the detection of bladder cancer. With a total of 2 patents to her name, her work has the potential to impact cancer diagnostics significantly.

Latest Patents

Isabelle Renard's latest patents include a method for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells. This patent discloses methods for assessing the methylation status of the TWIST1 gene, including bladder cells present in urine samples. Additionally, she has developed methods for detecting a predisposition to bladder cancer by identifying epigenetic changes in genes such as TWIST1, NID2, and RUNX3. These patents also include kits designed for performing these methods, which may contain means for processing urine samples.

Career Highlights

Isabelle Renard is currently associated with Mdxhealth, a company focused on molecular diagnostics. Her work at Mdxhealth emphasizes the importance of early detection and personalized medicine in cancer treatment.

Collaborations

Isabelle collaborates with Wim Van Criekinge, enhancing her research and development efforts in the field of cancer diagnostics.

Conclusion

Isabelle Renard's innovative work in the detection of bladder cancer through genetic analysis showcases her significant contributions to medical science. Her patents reflect a commitment to improving diagnostic methods, which could lead to better patient outcomes in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…